Literature DB >> 3229937

Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID).

G Lagrue1, J Laurent, D Belghiti.   

Abstract

The renal survival of 53 MPGN patients treated on a long-term basis by non-steroid anti-inflammatory drugs (NSAID) was compared to that of untreated MPGN patients previously reported in the literature. The difference between NSAID-treated and untreated patients (Habib's and Legrain's series) was significant by chi-square and logrank test performed during 10 and 14 years of follow-up. Our results were not significantly different from those observed by West in 45 MPGN children treated by steroids alone or in association with cytotoxic agents. After a follow-up of 14 years, 21 among our NSAID patients were in renal survival and 8 in end-stage renal disease (ESRD). They were respectively 11 and 3 in West' series, and for the untreated groups, 4 and 19 in Legrain's series and 1 and 33 in Habib's series.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3229937     DOI: 10.1007/bf02549501

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  24 in total

1.  [Comparative study on the activity of various anti-inflammatory agents in chronically developing glomerulonephritis].

Authors:  C P Giudicelli; G Lagrue; A Masbernard; G Hirbec
Journal:  J Urol Nephrol (Paris)       Date:  1975-09

2.  [Clinical study of niflumic acid in chronic glomerular nephropathy].

Authors:  G Lagrue; A Sobel; G Hirbec; M Kazandjian
Journal:  Sem Hop Ther       Date:  1977 May-Jun

3.  Use of a new anti-inflammatory agent, bucloxic acid, in the treatment of chronic glomerular nephropathies.

Authors:  G Lagrue; A Masbernard; C Giudicelli; G Hirbec
Journal:  Arzneimittelforschung       Date:  1974-09

4.  Idiopathic membranoproliferative glomerulonephritis in children. Report of 105 cases.

Authors:  R Habib; C Kleinknecht; M C Gubler; M Levy
Journal:  Clin Nephrol       Date:  1973 Jul-Aug       Impact factor: 0.975

5.  [Perspectives of indomethacin therapy in glomerular nephropathies].

Authors:  A Vercellone; G Piccoli; R Ragni; P L Cavalli
Journal:  Minerva Nefrol       Date:  1969 Mar-Apr

6.  [Treatment of primary glomerulopathies with an anti-inflammatory substance: indomethacin].

Authors:  G Lagrue; J Bariéty; P Druet; P Milliez
Journal:  Ann Med Interne (Paris)       Date:  1971-01

7.  [The prognosis in primary chronic glomerulonephritis in the adult. 298 clinicopathological cases (author's transl)].

Authors:  M Legrain; H Salah; H Beaufils; L Flores Esteves; J Guedon
Journal:  Nouv Presse Med       Date:  1978-02-18

8.  [Effects of an antiinflammatory drug (diclofenac) in primary chronic glomerulo-nephritis (author's transl)].

Authors:  G Lagrue; G Hirbec
Journal:  Sem Hop       Date:  1979 Oct 18-25

9.  Treatment of chronic glomerulonephritis with a combination of indomethacin and cyclophosphamide.

Authors:  Y Vanrenterghem; L Roels; R Verberckmoes; P Michielsen
Journal:  Clin Nephrol       Date:  1975-12       Impact factor: 0.975

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  2 in total

1.  Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.

Authors:  Martin H de Borst; Ferdau L Nauta; Liffert Vogt; Gozewijn D Laverman; Ron T Gansevoort; Gerjan Navis
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

2.  Delayed spontaneous resolution of nephrotic syndrome in a patient with hepatitis C virus-associated membranoproliferative glomerulonephritis.

Authors:  Gagangeet Sandhu; M Barry Stokes; Ira Meisels
Journal:  NDT Plus       Date:  2010-05-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.